Skip to main content
2025 AIUM Annual Convention - The Ultrasound Event Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Hands-On- Additional Fee
Hands-On- Additional Fee
Industry
Industry
Sold Out
Sold Out
Limited Space Available
Limited Space Available
Additional fee
Additional fee
Back

Alireza A. Shamshirsaz, MD

Professor
Boston Children's Hospital, Boston, MA
Boston, United States

Alireza A. Shamshirsaz, MD, FACOG, currently serves as the Director of the Maternal Fetal Care Center (MFCC) and Chief of the Maternal Fetal Medicine and Surgery Division at Boston Children’s Hospital. He has held the position of Professor of Surgery and Obstetrics and Gynecology at Harvard Medical School since 2022. Dr. Shamshirsaz is a Fetal Surgeon and is dual board-certified in obstetrics and gynecology, as well as maternal-fetal medicine. He also holds the positions of Vice Chair of the SMFM Education Committee, Co-editor in Chief of the Clinical Obstetrics and Gynecology Journal, and Chair of the Steering Committee of the North American Fetal Therapy Network (NAFTNet).

Over the course of his professional career in maternal-fetal medicine spanning two decades, he has published more than 300 peer-reviewed papers. These primarily focus on complex monochorionic pregnancies, lower urinary tract obstruction, neural tube defects, and placenta accreta spectrum disorders. He has also contributed to and led over 40 systematic reviews and meta-analyses in the field. Additionally, he has spearheaded several international qualitative studies aiming to establish clinical guidelines for controversial topics within the field.


In his current role, Dr. Shamshirsaz's research primarily centers on the following three domains:
1) Innovative Fetal Intervention: Dr. Shamshirsaz and his research team are exploring several innovative surgeries for patients with congenital hydrocephalus and vasa previa (FLUMEN study).
2) Innovative Medical Therapies: He has initiated multiple projects at his current position, including one examining the efficacy of Sirolimus in congenital cervicofacial malformations (MaterPons study).
3) Mesenchymal Stem Cells: His team is investigating the potential of MSCs in treating fetal anomalies.

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):